Facebook
Twitter
Telegram
Report an ErrorPLx Pharma Balance Sheet 2011-2024 | PLXP
Annual Balance Sheet PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -21.8 M | -9.72 M | -7.06 M | -17.5 M | -14.9 M | -5.23 M | -27 M | -3.86 M | -1.46 M | - |
Long Term Debt |
- | - | 622 K | 4.28 M | 6.94 M | - | - | - | - | - | - |
Long Term Debt Current |
- | 622 K | 3.66 M | 2.91 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 34 M | 24.5 M | 7.21 M | 22.4 M | - | - | - | - | - | - |
Total Current Liabilities |
11.9 M | 3.54 M | 6.09 M | 4.73 M | 1.82 M | - | - | - | - | - | - |
Total Liabilities |
25 M | 37.5 M | 30.6 M | 11.9 M | 24.2 M | 2.12 M | 1.61 M | 1.26 M | 824 K | 162 K | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-148 M | -102 M | -86.9 M | -66.4 M | -67.3 M | -62.4 M | -41.1 M | -22.3 M | - | - | - |
Total Assets |
76.6 M | 26.6 M | 18.5 M | 18.4 M | 28.8 M | 17.1 M | 32.4 M | 27.2 M | 4.03 M | 1.47 M | - |
Cash and Cash Equivalents |
69.4 M | 22.4 M | 14 M | 14.3 M | 24.4 M | 59.3 K | 5.23 M | 27 M | 3.86 M | - | - |
Book Value |
51.7 M | -10.9 M | -12.1 M | 6.44 M | 4.62 M | 15 M | 30.8 M | 25.9 M | 3.21 M | 1.31 M | - |
Total Shareholders Equity |
35.7 M | -10.9 M | -12.1 M | 6.44 M | 4.62 M | -2.32 M | 30.8 M | 25.9 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | 622 K | 622 K | 622 K | 622 K | 4.28 M | 4.28 M | 4.28 M | 4.28 M | 6.94 M | 6.94 M | 6.94 M | 6.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 7.02 M | 12 M | 18.9 M | 25 M | 44.9 M | 29.2 M | 22.3 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 2.94 M | 2.94 M | 2.94 M | 2.12 M | 1.61 M | 1.61 M | 1.61 M | 1.61 M | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 824 K | 824 K | 824 K | 824 K | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -179 M | -171 M | -159 M | -148 M | -152 M | -130 M | -114 M | -102 M | -102 M | -102 M | -102 M | -86.9 M | -86.9 M | -86.9 M | -86.9 M | -66.4 M | -66.4 M | -66.4 M | -66.4 M | -67.3 M | -67.3 M | -67.3 M | -67.3 M | -52 M | -52 M | -52 M | -62.4 M | -41.1 M | -41.1 M | -41.1 M | -41.1 M | -22.3 M | -22.3 M | -22.3 M | -22.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 33.2 M | 44.5 M | 60.9 M | 76.6 M | 91.8 M | 85.3 M | 88.3 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 616 K | 616 K | 616 K | 17.1 M | 32.4 M | 32.4 M | 32.4 M | 32.4 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 4.03 M | 4.03 M | 4.03 M | 4.03 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 25.8 M | 35.7 M | 52.5 M | 69.4 M | 82.6 M | 80.2 M | 84.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 14 M | 14 M | 14 M | 14 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 59.3 K | 59.3 K | 59.3 K | 16.7 M | 91.7 K | 5.23 M | 5.23 M | 5.23 M | 27 M | 27 M | 27 M | 27 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 1.46 M | - | - | - | - | - | - | - |
Book Value |
- | 26.2 M | 32.5 M | 42 M | 51.7 M | 46.9 M | 56.1 M | 66 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 4.62 M | 4.62 M | 4.62 M | 4.62 M | -2.32 M | -2.32 M | -2.32 M | 15 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 3.21 M | 3.21 M | 3.21 M | 3.21 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | 10.2 M | 16.5 M | 26 M | 35.7 M | 30.9 M | 40.1 M | 44.7 M | -10.9 M | -10.9 M | -10.9 M | -10.9 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 4.62 M | 4.62 M | 4.62 M | 4.62 M | -2.32 M | -2.32 M | -2.32 M | 15 M | 114 K | 30.8 M | 30.8 M | 30.8 M | 25.9 M | 25.9 M | 25.9 M | - | 3.21 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency